Imaging biomarkers for treatment development for impaired cognition: Report of the sixth CNTRICS meeting: Biomarkers recommended for further development

Schizophrenia Bulletin

Volumn 38, Issue 1, 2012, Pages 26-33

  Carter, Cameron S ^a   Barch, Deanna M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

biomarker; CNTRICS; cognition; cognitive neuroscience; EEG ERP; fMRI; neuroimaging; schizophrenia

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; COGNITION; COGNITIVE DEFECT; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; PRIORITY JOURNAL;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; COGNITION; COGNITION DISORDERS; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; HUMANS; MAGNETIC RESONANCE IMAGING; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); NEUROIMAGING; NEUROSCIENCES; SCHIZOPHRENIA; UNITED STATES;

EID: 84555188656     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbr109     Document Type: Article

References (21)

1. Barch DM. Pharmacological strategies for enhancing cognition in schizophrenia. Curr Top Behav Neurosci. 2010;4:43-96.
2. Carter CS, Barch DM, Bullmore E, et al. Cognitive neuroscience treatment research to improve cognition in schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biol Psychiatry. 2011;70:7-12.
3. Carter CS, Barch DM, Buchanan RW, et al. Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry. 2008;64:4-10.
4. Carter CS. Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia. Schizophr Bull. 2005;31: 810-815. (Pubitemid 41437774)
5. Carter CS, Barch DM. Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull. 2007;33:1131-1137. (Pubitemid 47347921)
6. Barch DM, Carter CS, Arnsten A, et al. Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull. 2009;35:109-114.
7. Barch DM, Carter CS. Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative. Schizophr Bull. 2008;34:613-618. (Pubitemid 351957561)
8. Cohen JD, Barch DM, Carter C, Servan-Schreiber D. Context-processing deficits in schizophrenia: converging evidence from three theoretically motivated cognitive tasks. J Abnorm Psychol. 1999;108:120-133. (Pubitemid 29108315)
9. Barch DM, Braver TS, Nystrom LE, Forman SD, Noll DC, Cohen JD. Dissociating working memory from task difficulty in human prefrontal cortex. Neuropsychologia. 1997;35:1373-1380. (Pubitemid 27455564)
10. Jones JA, Sponheim SR, MacDonald AW, III. The dot pattern expectancy task: reliability and replication of deficits in schizophrenia. Psychol Assess. 2010;22:131-141.
11. Ragland JD, Cools R, FrankM, et al. CNTRICS final task selection: long-term memory. Schizophr Bull. 2009;35:197-212.
12. Green MF, Butler PD, Chen Y, et al. Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS. Schizophr Bull. 2009;35:163-181.
13. Kozma-Wiebe P, Silverstein SM, Feher A, Kovacs I, Ulhaas P, Wilkniss SM. Development of a world-wide web based contour integration test. Comput Hum Behav. 2006;22:971-980.
14. Dakin S, Carlin P, Hemsley D. Weak suppression of visual context in chronic schizophrenia. Curr Biol. 2005;15:R822-R824. (Pubitemid 41501503)
15. Yoon JH, Rokem AS, Silver MA, et al. Diminished orientation-specific surround suppression of visual processing in schizophrenia. Schizophr Bull. 2009;35:1078-1084.
16. Vaidya CJ, Stollstorff M. Cognitive neuroscience of Attention Deficit Hyperactivity Disorder: current status and working hypotheses. Dev Disabil Res Rev. 2008;14:261-267.
17. Solomon M, Ozonoff SJ, Cummings N, Carter CS. Cognitive control in autism spectrum disorders. Int J Dev Neurosci. 2008;26:239-247.
18. Arnaiz E, Almkvist O. Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease. Acta Neurol Scand Suppl. 2003;179:34-41.
19. Barch DM, Mathalon DH. Using brain imaging measures in studies of procognitive pharmacologic agents in schizophrenia: psychometric and quality assurance considerations. Biol Psychiatry. 2011;70:13-18.
20. Luck SJ, Mathalon DH, O'Donnell BF, et al. A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research. Biol Psychiatry. 2011;70:28-34.
21. McClintock SM, Freitas C, Oberman L, Lisanby SH, Pascual-Leone A. Transcranial magnetic stimulation: a neuroscientific probe of cortical function in schizophrenia. Biol Psychiatry. 2011;70:19-27.